Relative contraindications such as significant kidney impairment or active gastrointestinal disease call for closer monitoring or specialist input instead
Generic companies are willing to invest tens of millions of dollars in patent litigation because they are competing for a time-limited, high-margin window that can be worth hundreds of millions or even billions for the right product
In these cases, individuals might actually experience weight loss rather than gain

These materials have legitimate applications within appropriate settings, and responsibility for their correct use rests with the purchaser. Nevertheless, UK Peptides also acknowledged wider concerns about standards across the sector, stating that greater clarity and consistency across the sector would be beneficial in supporting both public safety and industry accountability, particularly where it helps distinguish responsible suppliers from those operating without appropriate standards. UK Peptides emphasised that they place a strong emphasis on quality, consistency and traceability, [and] maintaining these standards is resource-intensive and represents a key distinction between established operators and lower-cost entrants. Dr Omar added: Banning the use of peptides would be a disservice to the public, but tighter controls on their sales may be an area that can be explored by regulators. For practitioners offering peptide therapies under medical supervision, the question of liability is not straightforward

It is not approved for any use as of June 2026, so eligibility is defined by the trials, not by a label
Hospital Pharmacies 6.3.1